

**Priv.- Doz. Dr. med. Diana Urban**

Neurologin und Expertin für seltene Muskelerkrankungen

## VERÖFFENTLICHUNGEN

### Originalarbeiten

1. **Lehmann, D.**; Zierz, S. Elektrophysiologie, Muskelbiopsie und Molekulargenetik in der Diagnose von Myopathien. *Nervenheilkunde* 2012, 31, 693-698, doi:10.1055/s-00034916. IF 0.06
2. **Lehmann, D.**; Zierz, S. Normal protein content but abnormally inhibited enzyme activity in muscle carnitine palmitoyltransferase II deficiency. *Journal of the neurological sciences* 2014, 339, 183-188, doi:10.1016/j.jns.2014.02.011. IF 2.651
3. Altmann, J.; Buchner, B.; Nadaj-Pakleza, A.; Schafer, J.; Jackson, S.; **Lehmann, D.**; Deschauer, M.; Kopajtich, R.; Lautenschlager, R.; Kuhn, K.A., et al. Expanded phenotypic spectrum of the m.8344A>G "MERRF" mutation: data from the German mitoNET registry. *Journal of neurology* 2016, 263, 961-972, doi:10.1007/s00415-016-8086-3. IF 4.204
4. **Lehmann, D.**; Kornhuber, M.E.; Clajus, C.; Alston, C.L.; Wienke, A.; Deschauer, M.; Taylor, R.W.; Zierz, S. Peripheral neuropathy in patients with CPEO associated with single and multiple mtDNA deletions. *Neurology. Genetics* 2016, 2, e113, doi:10.1212/NXG.0000000000000113. IF 3.509
5. **Lehmann, D.**; McFarland, R. Overview of Approaches to Mitochondrial Disease Therapy. *Journal of Inborn Errors of Metabolism and Screening* 2018, 6, 1-7, doi:10.1177/2326409817752960. kein IF
6. Motlagh Scholle, L.; **Lehmann, D.**; Joshi, P.R.; Zierz, S. Normal FGF-21-Serum Levels in Patients with Carnitine Palmitoyltransferase II (CPT II) Deficiency. *Int J Mol Sci* 2019, 20, doi:10.3390/ijms20061400. IF 4.556
7. **Lehmann, D.**; Tuppen, H.A.L.; Campbell, G.E.; Alston, C.L.; Lawless, C.; Rosa, H.S.; Rocha, M.C.; Reeve, A.K.; Nicholls, T.J.; Deschauer, M., et al. Understanding mitochondrial DNA maintenance disorders at the single muscle fibre level. *Nucleic acids research* 2019, 47, 7430-7443, doi:10.1093/nar/gkz472. IF 11.501
8. **Lehmann Urban, D.**; Motlagh Scholle, L.; Alt, K.; Ludolph, A.C.; Rosenbohm, A. Camptocormia as a Novel Phenotype in a Heterozygous POLG2 Mutation. *Diagnostics (Basel)* 2020, 10, doi:10.3390/diagnostics10020068. IF 3.110
9. Scholle, L.M.; Zierz, S.; Mawrin, C.; Wickenhauser, C.; **Lehmann Urban, D.** Heteroplasmy and Copy Number in the Common m.3243A>G Mutation-A Post-Mortem Genotype-Phenotype Analysis. *Genes (Basel)* 2020, 11, doi:10.3390/genes11020212. IF 3.759
10. **Lehmann Urban, D.**; Lehmann, E.; Motlagh Scholle, L.; Kraya, T. Myalgia in 30 Patients with Suspected Myopathy. *Int J Environ Res Public Health* 2020, 17, doi:10.3390/ijerph17072502. IF 2.849
11. **Lehmann Urban, D.**; Motlagh Scholle, L.; Wagner, M.; Ludolph, A.C.; Rosenbohm, A. The m.9143T>C Variant: Recurrent Infections and Immunodeficiency as an Extension

- of the Phenotypic Spectrum in MT-ATP6 Mutations? Diseases 2020, 8, 19, doi.org/10.3390/diseases8020019. No IF
12. Motlagh Scholle, L.; Schieffers, H.; Al-Robaiy, S.; Thaele, A.; Dehghani, F.; **Lehmann Urban, D.**; Zierz, S. The Effect of Resveratrol on Mitochondrial Function in Myoblasts of Patients with the Common m.3243A>G Mutation. Biomolecules 2020, 10, doi:10.3390/biom10081103. IF 4.082
  13. Motlagh Scholle, L.; Schieffers, H.; Al-Robaiy, S.; Thaele, A.; **Lehmann Urban, D.**; Zierz, S. Palmitate but Not Oleate Exerts a Negative Effect on Oxygen Utilization in Myoblasts of Patients with the m.3243A>G Mutation: A Pilot Study. Life 2020, 10(9), doi: 10.3390/life10090204. IF 2.991
  14. **Lehmann Urban, D.**; Mohamed, M.; Ludolph, A.C.; Kassubek, J.; Rosenbohm, A. The value of qualitative muscle MRI in the diagnostic procedures of myopathies: a biopsy-controlled study in 191 patients. Ther Adv Neurol Disord 2021, 14, 1756286420985256, doi:10.1177/1756286420985256. IF 5.000

#### Kasuistiken

1. **Lehmann, D.**; Schubert, K.; Joshi, P.R.; Baty, K.; Blakely, E.L.; Zierz, S.; Taylor, R.W.; Deschauer, M. A novel m.7539C>T point mutation in the mt-tRNA(Asp) gene associated with multisystemic mitochondrial disease. Neuromuscular disorders : NMD 2015, 25, 81-84, doi:10.1016/j.nmd.2014.09.008. IF 3.115
2. **Lehmann, D.**; Schubert, K.; Joshi, P.R.; Hardy, S.A.; Tuppen, H.A.; Baty, K.; Blakely, E.L.; Bamberg, C.; Zierz, S.; Deschauer, M., et al. Pathogenic mitochondrial mt-tRNA(Ala) variants are uniquely associated with isolated myopathy. Eur J Hum Genet 2015, 23, 1735-1738, doi:10.1038/ejhg.2015.73. IF 3.657
3. Reimann, J. \*; **Lehmann, D.** \*; Hardy, S.A.; Falkous, G.; Knowles, C.V.; Jones, R.L.; Kunz, W.S.; Taylor, R.W.; Kornblum, C. Camptocormia and shuffling gait due to a novel MT-TV mutation: Diagnostic pitfalls. Neurology. Genetics 2017, 3, e147, doi:10.1212/NXG.0000000000000147. geteilter IF 1.754

#### Übersichtsartikel

1. **Lehmann, D.** \*; Motlagh, L. \*; Robaa, D.; Zierz, S. Muscle Carnitine Palmitoyltransferase II Deficiency: A Review of Enzymatic Controversy and Clinical Features. Int J Mol Sci 2017, 18, doi:10.3390/ijms18010082. geteilter IF 2.278
2. **Lehmann, D.**; Debska-Vielhaber, G.; Motlagh, L.; Zierz, S.; Vielhaber, S. Therapie metabolischer Myopathien. Nervenheilkunde 2017, 36, 33-38, doi:10.1055/s-0038-1635069. IF 0.06
3. Scholle, L.M. \*; **Lehmann, D.** \*; Deschauer, M.; Kraya, T.; Zierz, S. FGF-21 as a Potential Biomarker for Mitochondrial Diseases. Curr Med Chem 2018, 25, 2070-2081, doi:10.2174/0929867325666180111094336. geteilter IF 1.497
4. Wurster, C.D.; Ludolph, A.C.; **Lehmann, D.**; Graf, H. Antisense-Oligonukleotide I; Chemische Modifikationen, Wirkmechanismen und therapeutischer Einsatz bei neurodegenerativen Erkrankungen. Nervenheilkunde 2018, 37, 809-817, doi:10.1055/s-0038-1675700. IF 0.06

5. Graf, H.; **Lehmann, D.**; Ludolph, A.C.; Wurster, C.D. Antisense-Oligonukleotide II; Therapeutisches Potenzial bei neuropsychiatrischen Erkrankungen sowie ethische und gesundheitspolitische Aspekte. *Nervenheilkunde* 2018, 37, 818-825, doi:10.1055/s-0038-1675711. IF 0.06
6. **Lehmann Urban, D.**; Schneider, I. [Gene-specific treatment approaches in muscle diseases]. *Nervenarzt* 2020, 91, 318-323, doi:10.1007/s00115-020-00870-8. IF 0.829

\* geteilte Erstautorenschaft